This company is no longer active
Ceapro (CZO) Stock Overview
A biotechnology company, engages in the development and marketing of health and wellness products and technology relating to plant extracts in the United States, Germany, China, Canada, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
CZO Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
An Undervalued 3.3Moz Gold Project in Canada
Key takeaways Upside Gold is developing the Kena Gold Project, near the town of Nelson in the Kootenays region of southern British Columbia. Kena hosts a historical gold resource of 3.33 million ounces (561,000 ounces Indicated and 2.77 million ounces Inferred) across a 10,200-hectare land package.
Read full narrativeCeapro Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.23 |
| 52 Week High | CA$0.54 |
| 52 Week Low | CA$0.15 |
| Beta | 1.38 |
| 1 Month Change | -8.16% |
| 3 Month Change | -2.17% |
| 1 Year Change | -51.09% |
| 3 Year Change | -67.86% |
| 5 Year Change | -42.31% |
| Change since IPO | -85.71% |
Recent News & Updates
Recent updates
Shareholder Returns
| CZO | CA Chemicals | CA Market | |
|---|---|---|---|
| 7D | -16.7% | -0.2% | 2.3% |
| 1Y | -51.1% | 45.7% | 34.5% |
Return vs Industry: CZO underperformed the Canadian Chemicals industry which returned 7.3% over the past year.
Return vs Market: CZO underperformed the Canadian Market which returned 11.9% over the past year.
Price Volatility
| CZO volatility | |
|---|---|
| CZO Average Weekly Movement | 8.8% |
| Chemicals Industry Average Movement | 9.8% |
| Market Average Movement | 10.3% |
| 10% most volatile stocks in CA Market | 17.8% |
| 10% least volatile stocks in CA Market | 4.0% |
Stable Share Price: CZO's share price has been volatile over the past 3 months.
Volatility Over Time: CZO's weekly volatility has decreased from 14% to 9% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | n/a | Gilles Gagnon | www.ceapro.com |
Ceapro Inc., a biotechnology company, engages in the development and marketing of health and wellness products and technology relating to plant extracts in the United States, Germany, China, Canada, and internationally. The company is involved in the development of proprietary extraction technologies and the application of these technologies to the production, development, and commercialization of active ingredients, such as oat beta glucan and avenanthramides, which are derived from oats and other renewable plant resources for healthcare and cosmetic industries. It also offers natural active ingredients, including oat powder, oat oil, oat peptides, and lupin peptides to the personal care, cosmetic, medical, and animal health industries; anti-aging skincare products to the cosmeceutical industries; and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner.
Ceapro Inc. Fundamentals Summary
| CZO fundamental statistics | |
|---|---|
| Market cap | CA$17.62m |
| Earnings (TTM) | -CA$4.71m |
| Revenue (TTM) | CA$9.63m |
Is CZO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CZO income statement (TTM) | |
|---|---|
| Revenue | CA$9.63m |
| Cost of Revenue | CA$5.68m |
| Gross Profit | CA$3.96m |
| Other Expenses | CA$8.67m |
| Earnings | -CA$4.71m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.06 |
| Gross Margin | 41.07% |
| Net Profit Margin | -48.89% |
| Debt/Equity Ratio | 0% |
How did CZO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/06/03 10:08 |
| End of Day Share Price | 2024/06/03 00:00 |
| Earnings | 2023/12/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Ceapro Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ahu Demir | NOBLE Capital Markets, Inc. |
| Cosme Ordoñez | NOBLE Capital Markets, Inc. |